Substance Abuse and Addiction Treatment, Global Markets to 2021
The global substance abuse and addiction treatment market reached $3.1 billion in 2016 and should reach nearly $4.4 billion in 2021, at a compound annual growth rate (CAGR) of 7.0%.
- An overview of the global market for substance abuse and addiction treatment therapeutics
- Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021
- Analyses of the market based on condition, treatment type, and region
- Discussion of the market dynamics, including drivers, restraints and opportunities
- An insight into the competitive landscape of the market through new product launches, mergers and acquisitions, and partnerships
- Profiles of the key players in the market
This report presents an in-depth analysis of the global substance abuse and addiction treatment market by conditions, treatments, and geographic markets; it includes the principal drug abuse conditions that are incorporated into several therapeutic treatment methods. This report examines the role of supply-chain members from manufacturers to researchers, and contains a comprehensive analysis of the dominant companies operating in the global substance abuse and addiction treatment market. The in-depth patent analysis section of the report will focus extensively on the technological trends across years and geographies such as the U.S., Europe and China.
This study considers the revenue generated by medications or therapeutics during the substance abuse treatment process. It does not review the expenses associated with services such as counseling, psychological therapy, rehabilitation or others. The report focuses on the substances that are either directly consumed or injected, hence the nicotine segment considers the medicines that help to treat smokeless tobacco addiction but does not take into account drugs that are only used for smoking cessation. The report examines all forms of opioids and cocaine in whichever form or mode they are ingested, and considers all types of alcohol abuse.
The market study is detailed for products based on applications as well as its further implication in the research and development area. These two segmentations are also discussed in depth for the given period. The market is broken down by the geographical regions of North America, Europe, Asia-Pacific and the ROW. Key market players operating in this market are Pfizer, GlaxoSmithKline, Alkermes, Teva Pharmaceuticals, Reckitt Benckiser, Forest Laboratories, and others totaling to about 20 companies.
Frequently Asked Questions (FAQs)
Yojana Jeevane has more than four years of experience in market intelligence and business research. She has experience in the healthcare domain with respect to medical devices, the life sciences market, and in the chemical domain. She has frequently delivered research services that contain strategic recommendations and top business strategies to help market players make strategic decision. She holds an MBA in Marketing.
- The U.S. market for substance abuse treatment and diagnosis increased slightly from $2.6 billion in 2007 to $2.7 billion in 2008. It should reach $3.1 billion in 2013, for a compound annual growth rate (CAGR) of 2.7%.
- Pharmaceutical treatments have the largest share of the market, worth $2.4 billion in 2007 and $2.5 billion in 2008. This should reach $2.8 billion in 2013, for a CAGR of 2.3%.
- Diagnostic testing is the second largest market segment, generating $216.0 million in 2007 and $230.0 million in 2008. This segment is expected to increase at a CAGR 5.9% to reach $307.0 million in 2013.
The total U.S. market for substance abuse treatment and diagnostics reached $1.1 billion in 2003 and, rising at an AAGR (average annual growth rate) of 4.1%, will reach $1.3 billion in 2008.
The pharmaceutical treatments segment accounts for the largest portion of revenues with an estimated $922.1 million in 2003. By 2008, this segment is expected to reach $1.09 billion, growing at an average annual rate of 3.5%.
Diagnostic testing products account for about 15% of the market, or revenues of $162.8 million in 2003. Technological advancements are expected to result in average annual growth of 7.1%, raising revenues to $229.6 million by 2008.